宝济药业-B今日盘中股价大幅上涨5.80%，市场表现强劲。
消息面上，公司此前宣布成功被纳入MSCI全球小型股指数成分股，相关调整将于5月底收市后正式生效。此次纳入有望为公司股票带来增量被动资金配置，提升市场流动性与国际知名度。此外，公司控股股东刘彦君博士此前宣布的增持计划仍在执行期内，叠加核心产品注射用KJ103拟纳入优先审评等多重利好因素，共同为股价提供了有力支撑。
宝济药业-B今日盘中股价大幅上涨5.80%，市场表现强劲。
消息面上，公司此前宣布成功被纳入MSCI全球小型股指数成分股，相关调整将于5月底收市后正式生效。此次纳入有望为公司股票带来增量被动资金配置，提升市场流动性与国际知名度。此外，公司控股股东刘彦君博士此前宣布的增持计划仍在执行期内，叠加核心产品注射用KJ103拟纳入优先审评等多重利好因素，共同为股价提供了有力支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.